Jaktinib (JAK1/2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)1507-1509
Number of pages3
JournalAmerican journal of hematology
Volume97
Issue number12
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Hematology

Cite this